Department of Preventive and Social Medicine, Jawaharlal Nehru Medical College, Sawangi Meghe, Wardha, India.
Indian J Pharmacol. 2013 Mar-Apr;45(2):195-6. doi: 10.4103/0253-7613.108322.
Early detection and treatment of early onset schizophrenia (EOS) can lead to better outcome. Aripiprazole, a partial agonist of dopamine and a second generation antipsychotic, has been approved specifically for treatment of children with schizophrenia of aged 13-17 years. Though the use of this drug in adults may be associated with worsening of psychosis in occasional cases, no such data is available in adolescents. We report a case of EOS, who had worsening of psychosis with aripiprazole monotherapy. We discuss the possible mechanisms and clinical implications relevant in adolescents, and alert the clinicians to be vigilant in monitoring the patients on aripiprazole, especially after an increase in the dose of this medication.
早期发现和治疗早发性精神分裂症（EOS）可以带来更好的结果。阿立哌唑是一种多巴胺部分激动剂和第二代抗精神病药物，专门批准用于治疗 13-17 岁患有精神分裂症的儿童。虽然这种药物在成年人中的使用可能会导致偶尔出现精神病恶化的情况，但在青少年中没有此类数据。我们报告了一例 EOS 患者，阿立哌唑单药治疗后精神病恶化。我们讨论了在青少年中相关的可能机制和临床意义，并提醒临床医生在监测阿立哌唑患者时要保持警惕，特别是在增加这种药物的剂量后。
